OVERVIEW OF ACTIVITY

Approximately 220,000 new cases of prostate cancer are diagnosed yearly in the United States, accounting for approximately one third of new cancer cases in men. Published results from clinical trials lead to the continuous emergence of novel surgical techniques, radiation therapy approaches and systemic agents, along with changes in the indications for existing treatments. In order to offer optimal patient care — including the option of clinical trial participation — the practicing urologist, radiation oncologist and medical oncologist must be well informed of these advances. To bridge the gap between research and practice, this issue of Prostate Cancer Update features roundtable discussions by our expert faculty of radiation oncologists, urologists and medical oncologists of recently published or presented papers in prostate cancer. By providing information on the latest research developments and expert perspectives, this CME activity assists clinicians with the formulation of up-to-date clinical management strategies.

LEARNING OBJECTIVES

• Evaluate the clinical implications of emerging research findings in prostate cancer treatment and surveillance, and incorporate these data into evidence-based management strategies.
• Assess the clinical utility of prostate cancer-specific prognostic markers and risk-assessment tools, including the systems pathology approach, in treatment decision-making.
• Compare and contrast the efficacy and side effects of longer- versus shorter-duration androgen deprivation therapy (ADT) for the adjunctive treatment of early and locally advanced prostate cancer.
• Appraise the data for neoadjuvant, concurrent and adjuvant ADT in combination with radiation therapy, and identify patients that may benefit from these therapeutic strategies.
• Counsel patients with prostate cancer about the impact of ADT on bone, cardiovascular and endocrine health.
• Delineate the potential risks and benefits of chemotherapy for nonmetastatic prostate cancer.
• Summarize emerging efficacy and safety data for targeted agents in castration-resistant prostate cancer, including specific endothelin A receptor antagonists and novel inhibitors of testosterone synthesis or activity.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity contains an audio component. To receive credit, the participant should review the CME information, listen to the audio and complete the Post-test and Educational Assessment and Credit Form located in our website at ResearchToPractice.com/PCU.

This program is supported by educational grants from AstraZeneca Pharmaceuticals LP and Aureon Laboratories Inc.